Expression of tumor necrosis factor α converting enzyme in endocrine cancers

American Journal of Clinical Pathology

Volumn 129, Issue 5, 2008, Pages 735-743

  Kirkegaard, Tove ^a,e   Naresh, Anjali ^b   Sabine, Vicky S ^d   Tovey, Sian M ^a   Edwards, Joanne ^a   Dunne, Barbara ^c   Cooke, Timothy G ^a   Jones, Frank E ^b   Barlett, John M S ^a,d  

^a University Department of Surgery   (United Kingdom)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Apoptosis; Endocrine cancers; HER4; Immunohistochemistry; TACE; Tumor necrosis factor converting enzyme

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANTIBODY DETECTION; APOPTOSIS; ARTICLE; BREAST CARCINOMA; ENDOCRINE TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; BIOSYNTHESIS; BREAST TUMOR; ENZYMOLOGY; GENE EXPRESSION; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ADAM PROTEINS; APOPTOSIS; BREAST NEOPLASMS; ENDOCRINE GLAND NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IN SITU NICK-END LABELING; MALE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN;

EID: 44849086153     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/N6YB6YDVF58YCNHN     Document Type: Article

References (42)

1. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol. 1998;10:654-659.
2. Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut. 2002;51:37-43.
3. Kirkegaard T, Pedersen G, Saermark T, et al. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol. 2004;135:146-153.
4. Patel IR, Attur MG, Patel RN, et al. TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha. J Immunol. 1998;160:4570-4579.
5. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729-733.
6. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385:733-736.
7. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281-1284.
8. Rio C, Buxbaum JD, Peschon JJ, et al. Tumor necrosis factor-alpha- converting enzyme is required for cleavage of erbB4/ HER4. J Biol Chem. 2000;275:10379-10387.
9. Borrell-Pages M, Rojo F, Albanell J, et al. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J. 2003;22:1114-1124.
10. Sunnarborg SW, Hinkle CL, Stevenson M, et al. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem. 2002;277:12838-12845.
11. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat. 1998;52:43-53.
12. Tidcombe H, Jackson-Fisher A, Mathers K, et al. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci U S A. 2003;100:8281-8286.
13. Stern DF. ErbBs in mammary development. Exp Cell Res. 2003;284:89-98.
14. Long W, Wagner KU, Lloyd KC, et al. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development. 2003;130:5257-5268.
15. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
16. Gullick WJ. c-erbB-4/HER4: friend or foe? J Pathol. 2003;200:279-281.
17. Lodge AJ, Anderson JJ, Gullick WJ, et al. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol. 2003;56:300-304.
18. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290-297.
19. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas: c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol. 2002;196:17-25.
20. Sartor CI, Zhou H, Kozlowska E, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 2001;21:4265-4275.
21. Tovey SM, Witton CJ, Bartlett JM, et al. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004;6:R246-R251.
22. Kew TY, Bell JA, Pinder SE, et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer. 2000;82:1163-1170.
23. Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006;66:6412-6420.
24. Vidal GA, Naresh A, Marrero L, et al. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem. 2005;280:19777-19783.
25. Cheng QC, Tikhomirov O, Zhou W, et al. Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem. 2003;278:38421-38427.
26. Ni CY, Yuan H, Carpenter G. Role of the ErbB-4 carboxyl terminus in gamma-secretase cleavage. J Biol Chem. 2003;278:4561-4565.
27. Lee HJ, Jung KM, Huang YZ, et al. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem. 2002;277:6318-6323.
28. Maatta JA, Sundvall M, Junttila TT, et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell. 2006;17:67-79.
29. Junttila TT, Sundvall M, Maatta JA, et al. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med. 2000;10:304-310.
30. Tovey S, Dunne B, Witton CJ, et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res. 2005;11:4835-4842.
31. Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992;340:329-333.
32. Kaye SB, Paul J, Cassidy J, et al, for the Scottish Gynecology Cancer Trials Group. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol. 1996;14:2113-2119.
33. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682-1691.
34. Vasey PA, Atkinson R, Coleman R, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer. 2001;84:170-178.
35. Vasey PA, Paul J, Birt A, et al, for the Scottish Gynaecological Cancer Trials Group. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol. 1999;17:2069-2080.
36. Tovey SM, Dunne B, Witton CJ, et al. HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4. Breast Cancer Res. 2006;8:R19.
37. Kirkegaard T, Edwards J, Tovey S, et al. Observer variation in immunohistochemical analysis of protein expression: time for a change? Histopathology. 2006;48:787-794.
38. Junttila TT, Sundvall M, Lundin M, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res. 2005;65:1384-1393.
39. Schantl JA, Roza M, Van Kerkhof P, et al. The growth hormone receptor interacts with its sheddase, the tumour necrosis factor-alpha-converting enzyme (TACE). Biochem J. 2004;377:379-384.
40. Bai M, Papoudou-Bai A, Horianopoulos N, et al. Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas. Hum Pathol. 2007;38:103-113.
41. Resendes AR, Majo N, Segales J, et al. Apoptosis in normal lymphoid organs from healthy normal, conventional pigs at different ages detected by TUNEL and cleaved caspase-3 immunohistochemistry in paraffin-embedded tissues. Vet Immunol Immunopathol. 2004;99:203-213.
42. Arthur CR, Gupton JT, Kellogg GE, et al. Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison. Biochem Pharmacol. 2007;74:981-991.